Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00783042 |
The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug effects.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis Inflammatory Activity in Coronary Arteries |
Drug: Rosuvastatin Drug: Placebo |
Phase 0 |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Transthoracic Doppler Echocardiography Method as a Non-Invasive Method for Coronary Function Measurements; Ability to Detect Short-Term Statin Effects in Patients With Increased Cardiovascular Risk |
Estimated Enrollment: | 80 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Rosuvastatin
40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
|
2: Placebo Comparator |
Drug: Placebo
Tablet, oral, once daily for 1 month (double blind)
|
Ages Eligible for Study: | 45 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Molndal Clinical Study Information | + 46 31 776 10 00 | maria.eriksson-lepkowska@astrazeneca.com |
Sweden | |
Research Site | Recruiting |
Goteborg, Sweden |
Principal Investigator: | Björn Fagerberg, MD, Professor | Wallenberg LaboratorySahlgrenska University Hospital, S-413 45 Göteborg |
Study Chair: | Maria Leonsson-Zachrissson, MD | AstraZeneca R&D Mölndal |
Responsible Party: | AstraZeneca Pharmaceuticals ( Björn Carlsson MD, PhD, Medical Science Director, Clinical Discovery Team CV/GI ) |
Study ID Numbers: | D1840M00006 |
Study First Received: | October 30, 2008 |
Last Updated: | October 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00783042 |
Health Authority: | Sweden: Medical Products Agency; Sweden: Regional Ethical Review Board |
TTDE-CFR coronary artery function cardiovascular biomarkers rosuvastatin Crestor |
Arterial Occlusive Diseases Atherosclerosis Rosuvastatin Vascular Diseases Arteriosclerosis |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents Enzyme Inhibitors |
Cardiovascular Diseases Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |